Independent Pharmacy Funding — Inventory, Reimbursement-Gap & Growth Capital
Independent pharmacy funding from Y Millennial Funding is working capital for independent retail, specialty, compounding and long-term-care pharmacies, structured as a merchant cash advance: a purchase of future receivables, not a loan. It covers the gap between paying the wholesaler and getting paid by PBMs and plans, and it is sized to the pharmacy's deposits for stores doing $50,000 or more a month. Not all applicants qualify.
Two changes made that gap harder to carry. Since January 2024, pharmacy price concessions come off at the point of sale instead of months later as DIR fees, which lowered reimbursement on every affected claim. And since January 1, 2026, the first ten drugs with negotiated Medicare prices are paid at the maximum fair price, with the difference refunded by the manufacturer afterward. Pharmacies use our funding to carry that float, stock brand and specialty inventory, and fund an acquisition or a new service line. We are a direct funder and underwrite on deposits, not credit score or collateral.
Get Pre-Qualified
Takes under a minute. No credit pull.
- Can I qualify with bad credit? No. Approval weighs your pharmacy's deposits and prescription revenue, not your credit score or collateral, so a pharmacy with steady scripts can qualify despite past credit issues. Not all applicants qualify.
- How fast can I get funded? Eligible applications with complete bank statements can get a same-day decision, with funding commonly within 24 to 72 hours.
- What does it cost? Advance size is based on monthly deposits and how consistent they are. We evaluate funding requests up to $5 million for high-volume and multi-location operations. Not all applicants qualify.
Industry Snapshot
Independent retail pharmacies; compounding pharmacies; specialty and long-term-care pharmacies; pharmacy-and-clinic combos; single-location and small-chain operators.
$50K-$5M monthly revenue typical for our applicants; many independent pharmacies in the $150K-$1M monthly range.
$25K-$500K typical advance size; larger advances available for high-volume and multi-location pharmacies with strong deposit history.
Why Traditional Lenders Struggle with Independent Pharmacies
Banks see thin, volatile margins and a balance sheet made of inventory and PBM receivables. Pharmacy inventory is expensive, perishable and often already subject to the wholesaler's security interest under its credit terms, so it is hard to lend against. Reimbursement rules have changed almost every year, so two years of tax returns describe a store that no longer gets paid the same way.
In an acquisition, most of the value is the prescription files, which a bank won't count as collateral.
Why Revenue-Based Funding Works for Independent Pharmacies
A merchant cash advance reads the pharmacy's deposits, including PBM remittances, front-end sales, copays and cash, and sizes funding to that history rather than to margins on a tax return. Remittance is a share of receivables, so it flexes when a PBM pays late.
Pharmacies use it for timing gaps: the maximum-fair-price refund float, a large specialty order, a new long-term-care contract, or buying a closing store's files. It is not a fix for a store whose reimbursement doesn't cover its drug cost, and we'll say so if that is what the statements show.
A merchant cash advance is a purchase of future receivables, not a loan. Approval depends on underwriting and revenue, and not all applicants qualify.
See if your independent pharmacies business pre-qualifies
Checking your options takes under a minute and won't affect your credit. Approved on revenue, not credit score.
Prefer to talk? Call (855) 774-6461Common Uses of Funding
Carrying the maximum-fair-price refund float and PBM payment lag; buying brand, specialty and GLP-1 inventory; taking on a new long-term-care or assisted-living contract; buying a closing store's prescription files or another pharmacy; adding compounding, delivery or clinical services; pharmacy system upgrades and renovation.
Common Challenges
The wholesaler bill doesn't wait for the PBM. Drugs are bought on short wholesaler terms, while plans pay on their own schedule; Medicare Part D sponsors must pay clean electronic claims within 14 days, and commercial PBMs can take longer.
Paid below cost. With price concessions built into point-of-sale reimbursement since 2024, some claims pay less than the store paid for the drug, and early 2024 hit twice: lower point-of-sale rates while DIR from 2023 was still being clawed back.
The MFP float. For Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara and NovoLog/Fiasp, the Part D plan now pays based on the negotiated price, and the manufacturer owes the pharmacy the difference through the Medicare Transaction Facilitator within 14 days. The pharmacy has already paid the wholesaler full price, and 15 more drugs are scheduled for 2027.
Brand and specialty inventory ties up cash. A handful of GLP-1, biologic or oncology scripts can mean thousands of dollars sitting on the shelf.
Audits and recoupments. A PBM audit can claw back payment on claims months after they were filled over documentation issues.
Long-term-care pharmacies feel all of it more, because their mix leans heavily on the branded drugs the negotiation program covers.
How Repayment Works
Daily or weekly ACH remittance set as a percentage of revenue, so remittance flexes with actual collections. Total terms typically range from 6 to 18 months depending on advance size and deposit consistency.
Seasonal Considerations
Volume is steady year-round, with flu and immunization season lifting traffic from September through November. January matters most for cash: the Part D plan year resets on January 1 with new formularies, network terms and patient deductibles, and it is also when new rounds of negotiated Medicare prices take effect, starting with 2026 and the next 15 drugs in 2027. Specialty drug demand is not seasonal.
Regulatory Environment
State board of pharmacy licensing and pharmacist-in-charge rules; DEA registration for controlled substances; Medicare Part D and Medicaid participation, including Part D's 14-day prompt-pay standard for clean electronic claims; PBM contracts and state PBM laws, which vary widely; the Medicare Drug Price Negotiation Program, in effect since January 1, 2026 for the first ten drugs; USP <795> and <797> for compounding; the Drug Supply Chain Security Act's tracing requirements; and HIPAA.
Industry Terminology
PBM, DIR fee, reimbursement spread, AWP, MAC pricing, fill, script count, generic dispensing rate, 340B, specialty, compounding, Part D, claw-back, adjudication, central fill.
Nationwide Independent Pharmacies Funding
Y Millennial Funding works with independent pharmacies businesses across the United States. Because our funding is revenue-based and delivered electronically via ACH, we are able to work with businesses nationwide — not just in a single region. Wherever your business operates, we can underwrite based on your revenue history and get you funded quickly.
Local Markets We Serve
We fund Independent Pharmacies businesses nationwide — browse all locations.Frequently Asked Questions
Common questions about independent pharmacies business funding.
Related Industries
Helpful Tools
Free resources to help you understand and plan your merchant cash advance.
Eligibility Checker
5-minute pre-qualification assessment with no credit pull.
MCA Calculator
Estimate payments, factor-rate cost, APR, and term length.
Stacking Calculator
Analyze capacity for multiple MCA positions.
How MCA Works
Learn the mechanics and process.
MCA Disclosures
Important terms and information.